GeNeuro’s Pipeline Overview

GeNeuro’s approach involves targeting and neutralizing pathogenic proteins encoded by human endogenous retroviruses (HERV) which could play a causal role in the development of disorders with complex etiology, notably autoimmune and neurodegenerative disorders.

In multiple sclerosis, GeNeuro is testing a therapeutic antibody against the envelope protein of the endogenous retrovirus pHERV-W, which may be a causative factor in the inflammation and neurodegeneration characteristic of multiple sclerosis. GeNeuro believes that the neutralization of this protein is the first therapeutic approach against a causative factor of the disease.

GeNeuro capitalizes on the potential of its technology by developing an exclusive therapeutic platform focused on diseases potentially caused by human endogenous retroviruses. In April 2017, GeNeuro began a Phase IIa study in 60 patients affected by Type 1 diabetes. Type diabetes is presumed to be an autoimmune-mediated disease. In pathological studies, over 50% of Type 1 diabetes patients were found to express the pathogenic HERV-W Env protein in their pancreas. Both in vitro and in vivo studies in animal models suggest pHERV-W Env could play a causal role in the disease. Other indications targeted by GeNeuro include CIDP (chronic inflammatory demyelinating polyneuropathy), a rare inflammatory disease of peripheral nerves, where a Phase IIa study is planned.

To capture the full therapeutic potential of its approach against pathogenic HERV proteins, GeNeuro is developing other monoclonal antibodies, currently at preclinical stage, against inflammatory psychosis, as well as against amyotrophic lateral sclerosis, in a research partnership with the US NIH.

GeNeuro is also attempting to develop diagnostic tests to test for pathogenic HERV proteins in patients. These tests would detect the presence of the antigen in the blood of patients and could be used as companion diagnostics in a personalized medicine approach.